The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 14, 2011
Filed:
Mar. 30, 2006
Masaaki Hirano, Tokyo, JP;
Isao Kinoyama, Tokyo, JP;
Shunichiro Matsumoto, Tokyo, JP;
Eiji Kawaminami, Tokyo, JP;
Kei Ohnuki, Tokyo, JP;
Hirofumi Yamamoto, Tokyo, JP;
Kazuhiko Osoda, Tokyo, JP;
Tatsuhisa Takahashi, Tokyo, JP;
Takashi Shin, Tokyo, JP;
Takanori Koike, Tokyo, JP;
Itsuro Shimada, Tokyo, JP;
Hiroyuki Hisamichi, Tokyo, JP;
Toshiyuki Kusayama, Tokyo, JP;
Masaaki Hirano, Tokyo, JP;
Isao Kinoyama, Tokyo, JP;
Shunichiro Matsumoto, Tokyo, JP;
Eiji Kawaminami, Tokyo, JP;
Kei Ohnuki, Tokyo, JP;
Hirofumi Yamamoto, Tokyo, JP;
Kazuhiko Osoda, Tokyo, JP;
Tatsuhisa Takahashi, Tokyo, JP;
Takashi Shin, Tokyo, JP;
Takanori Koike, Tokyo, JP;
Itsuro Shimada, Tokyo, JP;
Hiroyuki Hisamichi, Tokyo, JP;
Toshiyuki Kusayama, Tokyo, JP;
Astellas Pharma Inc., Tokyo, JP;
Abstract
It is intended to provide a compound useful as a GnRH receptor antagonist. The inventors further investigated propane-1,3-dione derivatives. As a result, they confirmed that a compound having a benzene ring or a thiophene ring substituted with a group represented by —SO—Rin a propane-1,3-dione derivative having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene) has an excellent GnRH receptor antagonistic effect and accomplished the present invention. Because the compound of the present invention has a potent GnRH receptor antagonistic effect, it is useful for the treatment of sex hormone-dependent diseases, particularly GnRH-related diseases. Further, because the compound of the present invention has an excellent metabolic stability in human and few drug interactions, therefore it has preferable characteristics as a pharmaceutical used for the above-mentioned diseases.